p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant.

Prior to this study, the p53 null phenotype was not well described in urothelial carcinoma of the bladder. Abnormal p53 immunoexpression (null staining pattern or staining in >50% of cells) is prognostic in terms of oncological outcome.